misoprostol efficiency in postpartum hemorrhage.

The comparison of efficiency of misoprostol used in different ways in postpartum hemorrhage.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR201812901591120

Enrollment

400

Registered

2018-12-06

Start date

2018-10-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum hemorrhage

Interventions

Experimental oral misoprostol group

Experimental sublingual misoprostol group

Experimental buccal misoprostol group

Plaseco group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women between the ages of 18-40 2. Having pregnancy between 37-42 weeks 3. Women on vaginal delivery 4. Pregnant women with BMI <35 5. Nulliparity

Exclusion criteria

Exclusion criteria: 1. Women with multiple pregnancy 2. Pregnant women with myoma 3. Pregnant women with polyhydramnios 4. Pregnant women with chorioamnionitis 5. Pregnant women with placental abnormalities 6. Pregnant women with bleeding diathesis 7. Pregnant women with caesarean 8. Pregnant women with low platelet 9. Women who do not want to participate 10. Pregnant women with allergic reactions to drug

Design outcomes

Primary

Measure	Time frame
Objective measurement of blood collected in the bucket under the postpartum table, prenatal and postnatal 6th hours hemoglobin levels will be recorded.	—

Secondary

Measure	Time frame
primary or secondary postpartum hemorrhage will be observed.	—

Countries

Somalia

Contacts

Public ContactSamaara Hassan

Miss.

samaara010@gmail.com+252615937497

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026